title: Complementarity-determining region 3 size spectratypes of T cell receptor beta chains in CD8+ T cells following antiviral treatment of chronic hepatitis B.
abstract: An increased CD8(+) T cell response to hepatitis B virus (HBV) peptides occurs between 12 and 24 weeks after starting antiviral therapy for chronic hepatitis B. It is not known whether these cells have antiviral function. The aim of this study was to determine whether clonal expansions of CD8(+) T cells at these time points predict the virological response to therapy. Peripheral blood CD8(+) T cells were obtained from 20 patients treated with lamivudine or telbivudine for chronic hepatitis B at baseline, 12 weeks, and 24 weeks. The CDR3 spectratype of each T cell receptor (TCR) β chain variable region (Vβ) gene family was analyzed, and the changes in the numbers of Vβ families with clonal expansions were compared in subjects with (n = 12) and without (n = 8) a virological response (52 week HBV DNA < 300 copies/ml). The number of CD8(+) TCR Vβ families with clonal expansions at 12 weeks relative to baseline (median [10th to 90th percentile], +2.5 [0 to +7] versus +1 [0 to +2], P = 0.03) and at 24 weeks relative to 12 weeks (+1 [0 to +2] versus -1 [-3 to +4], P = 0.006) was higher in subjects with a virological response versus subjects without a virological response, as were interleukin-2 (IL-2) but not IL-21 mRNA levels in peripheral blood mononuclear cells. The duration of new expansions at 12 weeks was higher (P < 0.0001) in responders. Increased numbers of CD8(+) T cell expansions after antiviral therapy are associated with a virological response to treatment. These CD8(+) T cells are a potential target for a therapeutic vaccine for chronic hepatitis B.
authors.affiliation: Hepatology Unit and Key Laboratory for Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.
authors.forename: Shi-Wu
authors.initials: SW
authors.lastname: Ma
authors.forename: Yong-Yin
authors.initials: YY
authors.lastname: Li
authors.forename: Guang-Wen
authors.initials: GW
authors.lastname: Zhang
authors.forename: Xuan
authors.initials: X
authors.lastname: Huang
authors.forename: Jian
authors.initials: J
authors.lastname: Sun
authors.forename: Chris
authors.initials: C
authors.lastname: Li
authors.forename: William G H
authors.initials: WG
authors.lastname: Abbott
authors.forename: Jin-Lin
authors.initials: JL
authors.lastname: Hou
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D022801:Complementarity Determining Regions / Q000235:genetics*; D004311:Double-Blind Method; D005260:Female; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy / Q000276:immunology* / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D009705:Nucleosides / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction / Q000379:methods; D011744:Pyrimidinones / Q000627:therapeutic use*; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D000077712:Telbivudine; D013936:Thymidine / Q000031:analogs & derivatives; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D022801:Complementarity Determining Regions; D009705:Nucleosides; D011744:Pyrimidinones; D016693:Receptors, Antigen, T-Cell, alpha-beta; D000077712:Telbivudine; D019259:Lamivudine; D013936:Thymidine